Rasagiline Tablets

The government is procuring Rasagiline tablets (0.5 mg and 1 mg, 30‑count bottles) for DLA and VA pharmaceutical prime‑vendor programs. Offerors must submit a full electronic offer through DIBBS that includes two volumes – a non‑price technical proposal (SF 1449, trade‑agreement and country‑of‑origin charts, representations and certifications, subcontracting plan (large businesses), letters of commitment or certification, FDA compliance disclosures, and required contact and facility information) and a price proposal (unit price per bottle for the base year and up to four option years). The solicitation does not present a menu of multiple product lines or lots; it is a single‑item requirement. The contract will be performed in the United States (place‑of‑performance clause) on a firm‑fixed‑price requirements basis, with a one‑year base period and four one‑year options (maximum five‑year term), and is not set‑aside to a specific small‑business category.

Notice ID

0fea2a329f844c848072c9a0f24cfc4f

Solicitation Number

SPE2D2-25-R-0020

NAICS Code

325412

Classification Code

6505